Sarcomatrix's crowdfunding campaign raised only $52k while costing $40k in marketing. The CEO learned that for diseases like muscular dystrophy, the high cost of patient care leaves friends and family with little extra money to invest, a critical and costly miscalculation for this fundraising model.
Sarcomatrix used its first non-institutional funds for a CMC campaign to find new salt variants. This addressed a key investor concern about its IP, which was only method patents. The new polymorph and salt patents extended the drug's potential runway to 2047, making the company significantly more valuable and fundable.
David Craig advises against fully entrusting manufacturing to a CDMO. He keeps a Chief Technical Officer in-house to manage the project plan's minutiae. This internal oversight prevents missed timelines and manages rate-limiting steps, which often derail virtual programs relying solely on external partners for execution.
When pursuing non-traditional financing, founders should map out all early funding rounds at once. This ensures each capital injection incrementally adds value and is structured to avoid roadblocks for the next, larger round. It prevents messy cap tables or terms from non-standard vehicles like crowdfunding that deter future institutional investors.
At early Amgen, a Friday beer session was a dedicated time to clear the air between colleagues who had conflicts during the week. David Craig applies this principle of scheduled "repair" to virtual companies, advocating for annual face-to-face meetings to ensure personal conflicts don't fester in a remote environment.
Sarcomatrix's CEO secured six-figure checks by entering pitch contests at unrelated venues like Freedom Fest, a libertarian conference. This face-to-face interaction with high-net-worth individuals in unexpected settings proved more effective for early funding than cold outreach to traditional VCs.
While operating a lean virtual model, Sarcomatrix's CEO advises against outsourcing three core functions. The CEO provides essential leadership, the company is ultimately responsible for quality systems regardless of its CROs, and owning the regulatory interface directly builds crucial credibility with agencies.
Sarcomatrix's CEO compares the muscular dystrophy market (90 clinics, 450 physicians) to the early, concentrated markets for Amgen (dialysis centers) and Gilead (AIDS clinics). This structure allows a startup to become a fully integrated company with a small, focused sales team, a key factor in its commercial viability.